



(43) International Publication Date
3 October 2013 (03.10.2013)

(10) International Publication Number
WO 2013/144249 A1

(51) International Patent Classification:

A61K 31/4439 (2006.01) *G11B 20/00* (2006.01)
A61P 35/00 (2006.01) *C12N 15/11* (2006.01)
C12Q 1/68 (2006.01)

(21) International Application Number:

PCT/EP2013/056600

(22) International Filing Date:

27 March 2013 (27.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/617,284 29 March 2012 (29.03.2012) US
61/767,848 22 February 2013 (22.02.2013) US

(71) Applicant (for all designated States except US): **NO-VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **FURET, Pascal** [FR/CH]; c/o Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-7057 Basel (CH). **FRITSCH, Christine** [FR/CH]; c/o Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel (CH). **MAIRA, Sauveur-Michel** [FR/CH]; c/o Novartis Pharma AG, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel (CH).

(74) Agent: **RUDGE, Sewkian**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: PHARMACEUTICAL DIAGNOSTIC

(57) Abstract: The invention is directed, in part, to selective cancer treatment regimes based on assaying for the presence or absence of a mutation in a nucleic acid that encodes glutamine at position 859 of the catalytic p110 α subunit of PI3K.



WO 2013/144249 A1